RU2017145602A - Жидкие композиции целекоксиба для перорального введения - Google Patents
Жидкие композиции целекоксиба для перорального введения Download PDFInfo
- Publication number
- RU2017145602A RU2017145602A RU2017145602A RU2017145602A RU2017145602A RU 2017145602 A RU2017145602 A RU 2017145602A RU 2017145602 A RU2017145602 A RU 2017145602A RU 2017145602 A RU2017145602 A RU 2017145602A RU 2017145602 A RU2017145602 A RU 2017145602A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical preparation
- weight
- amount
- volume
- preparation according
- Prior art date
Links
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 title claims 9
- 229960000590 celecoxib Drugs 0.000 title claims 9
- 239000007788 liquid Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 12
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 10
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims 10
- 238000000034 method Methods 0.000 claims 7
- 235000011187 glycerol Nutrition 0.000 claims 5
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 5
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims 5
- 229960002216 methylparaben Drugs 0.000 claims 5
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims 5
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims 5
- 229960003415 propylparaben Drugs 0.000 claims 5
- 239000000725 suspension Substances 0.000 claims 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 5
- 239000000230 xanthan gum Substances 0.000 claims 5
- 229920001285 xanthan gum Polymers 0.000 claims 5
- 229940082509 xanthan gum Drugs 0.000 claims 5
- 235000010493 xanthan gum Nutrition 0.000 claims 5
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 claims 4
- 239000000796 flavoring agent Substances 0.000 claims 4
- 235000019634 flavors Nutrition 0.000 claims 4
- 239000004615 ingredient Substances 0.000 claims 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 241000219095 Vitis Species 0.000 claims 3
- 235000009754 Vitis X bourquina Nutrition 0.000 claims 3
- 235000012333 Vitis X labruscana Nutrition 0.000 claims 3
- 235000014787 Vitis vinifera Nutrition 0.000 claims 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- LRZSAGKIMYFLHY-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;dihydrate Chemical compound O.O.OC(=O)CC(O)(C(O)=O)CC(O)=O LRZSAGKIMYFLHY-UHFFFAOYSA-N 0.000 claims 1
- 239000004376 Sucralose Substances 0.000 claims 1
- HZVVJJIYJKGMFL-UHFFFAOYSA-N almasilate Chemical compound O.[Mg+2].[Al+3].[Al+3].O[Si](O)=O.O[Si](O)=O HZVVJJIYJKGMFL-UHFFFAOYSA-N 0.000 claims 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 claims 1
- 229910000397 disodium phosphate Inorganic materials 0.000 claims 1
- 235000019800 disodium phosphate Nutrition 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims 1
- 235000019408 sucralose Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562168012P | 2015-05-29 | 2015-05-29 | |
| US62/168,012 | 2015-05-29 | ||
| US15/163,258 US20160346300A1 (en) | 2015-05-29 | 2016-05-24 | Liquid formulations of celecoxib for oral administration |
| PCT/US2016/033937 WO2016196085A1 (en) | 2015-05-29 | 2016-05-24 | Liquid formulations of celecoxib for oral administration |
| US15/163,258 | 2016-05-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017145602A true RU2017145602A (ru) | 2019-07-02 |
| RU2017145602A3 RU2017145602A3 (enExample) | 2019-11-25 |
Family
ID=57396976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017145602A RU2017145602A (ru) | 2015-05-29 | 2016-05-24 | Жидкие композиции целекоксиба для перорального введения |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20160346300A1 (enExample) |
| EP (1) | EP3302430A4 (enExample) |
| JP (1) | JP2018516279A (enExample) |
| AU (1) | AU2016270504A1 (enExample) |
| BR (1) | BR112017025527A2 (enExample) |
| CA (1) | CA2987388A1 (enExample) |
| MX (1) | MX2017015202A (enExample) |
| RU (1) | RU2017145602A (enExample) |
| WO (1) | WO2016196085A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016191744A1 (en) * | 2015-05-28 | 2016-12-01 | Dr. Reddy's Laboratories Ltd. | Oral composition of celecoxib for treatment of pain |
| WO2022185338A1 (en) * | 2021-03-05 | 2022-09-09 | Alkem Laboratories Limited | Stable oral suspension of celecoxib and method of preparation thereof |
| CN115737554B (zh) * | 2022-11-28 | 2024-07-09 | 宜昌人福药业有限责任公司 | 一种氯巴占口服混悬剂的制备方法 |
| WO2024142089A1 (en) * | 2022-12-27 | 2024-07-04 | Cipla Limited | Injectable compositions of celecoxib |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4145440A (en) * | 1977-08-18 | 1979-03-20 | The Upjohn Company | Liquid suspension of an aluminum salt of ibuprofen |
| IN191512B (enExample) * | 2000-01-21 | 2003-12-06 | Panacea Biotech | |
| MXPA02010259A (es) * | 2000-04-18 | 2003-12-11 | Pharmacia Corp | Formulacion de accion rapida de un inhibidor selectivo de ciclooxigenasa-2. |
| AR035642A1 (es) * | 2000-05-26 | 2004-06-23 | Pharmacia Corp | Uso de una composicion de celecoxib para el alivio rapido del dolor |
| US6656505B2 (en) * | 2000-07-21 | 2003-12-02 | Alpharma Uspd Inc. | Method for forming an aqueous flocculated suspension |
| US20030105144A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
| UA80682C2 (en) * | 2001-08-06 | 2007-10-25 | Pharmacia Corp | Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition |
| US7101572B2 (en) * | 2001-12-07 | 2006-09-05 | Unilab Pharmatech, Ltd. | Taste masked aqueous liquid pharmaceutical composition |
| PL371133A1 (en) * | 2001-12-20 | 2005-06-13 | Pharmacia Corporation | Pharmaceutical suspension for oral administration |
| AU2003238221A1 (en) * | 2002-06-17 | 2003-12-31 | Taro Pharmaceuticals U.S.A, Inc. | Ibuprofen suspension |
| US20060148877A1 (en) * | 2002-11-26 | 2006-07-06 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations of celcoxib |
| US20050014729A1 (en) * | 2003-07-16 | 2005-01-20 | Pharmacia Corporation | Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith |
| US20050266031A1 (en) * | 2004-05-25 | 2005-12-01 | Jay Dickerson | Pharmaceutical suspension composition |
| US20080014274A1 (en) * | 2006-07-14 | 2008-01-17 | Wyeth | Enhanced stability phenylephrine liquid compositions |
| US20110183944A1 (en) * | 2010-01-28 | 2011-07-28 | Paul Ashton | SUSTAINED-RELEASE NSAID/HMG CoA REDUCTASE INHIBITOR COMPOSITIONS |
| EP3530268B1 (en) * | 2012-10-09 | 2021-12-15 | Attentive Therapeutics, Inc. | Therapeutic treatment |
| CN103932977A (zh) * | 2014-04-15 | 2014-07-23 | 江苏正大清江制药有限公司 | 一种塞来昔布制剂的制备方法 |
-
2016
- 2016-05-24 WO PCT/US2016/033937 patent/WO2016196085A1/en not_active Ceased
- 2016-05-24 EP EP16804009.5A patent/EP3302430A4/en not_active Withdrawn
- 2016-05-24 US US15/163,258 patent/US20160346300A1/en not_active Abandoned
- 2016-05-24 AU AU2016270504A patent/AU2016270504A1/en not_active Abandoned
- 2016-05-24 RU RU2017145602A patent/RU2017145602A/ru not_active Application Discontinuation
- 2016-05-24 BR BR112017025527A patent/BR112017025527A2/pt not_active Application Discontinuation
- 2016-05-24 CA CA2987388A patent/CA2987388A1/en not_active Abandoned
- 2016-05-24 MX MX2017015202A patent/MX2017015202A/es unknown
- 2016-05-24 JP JP2018513730A patent/JP2018516279A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017015202A (es) | 2018-07-06 |
| RU2017145602A3 (enExample) | 2019-11-25 |
| AU2016270504A1 (en) | 2017-12-14 |
| CA2987388A1 (en) | 2016-12-08 |
| US20160346300A1 (en) | 2016-12-01 |
| WO2016196085A1 (en) | 2016-12-08 |
| JP2018516279A (ja) | 2018-06-21 |
| EP3302430A4 (en) | 2019-05-29 |
| EP3302430A1 (en) | 2018-04-11 |
| BR112017025527A2 (pt) | 2018-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101695580B1 (ko) | 증가된 안정성의 신규한 액체 조성물 | |
| RU2017145602A (ru) | Жидкие композиции целекоксиба для перорального введения | |
| CA2567075A1 (en) | Pharmaceutical suspension composition | |
| KR20070024722A (ko) | 저작에 대하여 안정적인 캡슐 | |
| RU2668882C2 (ru) | Жидкая фармацевтическая композиция | |
| KR101947198B1 (ko) | 수난용성 약물 함유 의약 조성물 | |
| US20140371242A1 (en) | Azathioprine Oral Suspensions and Methods of Use | |
| TWI622408B (zh) | 用於口服之可嚼組合物及其製備方法 | |
| WO2005000279A1 (ja) | 硬カプセル剤 | |
| JP6371379B2 (ja) | ヒドロコルチゾンを含有する組成物 | |
| US20160120988A1 (en) | Pazopanib formulation | |
| US20070026075A1 (en) | Gelled donepezil compositions and methods for making and using the same | |
| RU2015143993A (ru) | Твердые лекарственные формы, обладающие противорвотным действием, с замедленным высвобождением | |
| JP4580921B2 (ja) | ５−メチル−２−（２’−クロロ−６’−フルオロアニリノ）フェニル酢酸を含む医薬組成物 | |
| CN103610645B (zh) | 一种非索非那定盐酸盐的药物组合物及制备方法 | |
| Vasani et al. | Preparation and evaluation of chocolate drug delivery system of albendazole | |
| WO2009112800A1 (en) | Losartan composition | |
| JP2016121073A (ja) | 注射剤用医薬組成物の製造方法 | |
| EP3593819A1 (en) | Compositions for therapeutic uses containing 5-htp and carbidopa | |
| JP2004522698A (ja) | 医薬組成物のための香料系およびそのような組成物の製造方法 | |
| CN103705459A (zh) | 一种结晶性头孢噻呋游离酸纳米乳注射剂及其制备方法 | |
| WO2013062497A1 (en) | Liquid pharmaceutical formulations | |
| JP6732351B1 (ja) | イソクエルシトリン組成物 | |
| JP2004099559A (ja) | 医薬用ゼリー組成物 | |
| CN104337820A (zh) | 一种含乙酰水杨酸+甲基强的松龙混悬液及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20200317 |